<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/CB90AF84-0C45-4AE3-A91A-5F9EDBE89398"><gtr:id>CB90AF84-0C45-4AE3-A91A-5F9EDBE89398</gtr:id><gtr:name>Cell Therapy Catapult</gtr:name><gtr:address><gtr:line1>12th Floor Tower Wing, Guys Hospital, 
Great Maze Pond,</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SE1 9RT</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/CB90AF84-0C45-4AE3-A91A-5F9EDBE89398"><gtr:id>CB90AF84-0C45-4AE3-A91A-5F9EDBE89398</gtr:id><gtr:name>Cell Therapy Catapult</gtr:name><gtr:address><gtr:line1>12th Floor Tower Wing, Guys Hospital, 
Great Maze Pond,</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SE1 9RT</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/241F1346-5943-46D8-8C06-9C502D38443C"><gtr:id>241F1346-5943-46D8-8C06-9C502D38443C</gtr:id><gtr:firstName>Farzin</gtr:firstName><gtr:surname>Farzaneh</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=BB%2FD014301%2F1"><gtr:id>70F8B258-365B-4B32-B426-912D697BDCB5</gtr:id><gtr:title>SPONTANEOUSLY BIOTINYLATED LENTIVIRAL VECTORS FOR ENVELOPE INDEPENDENT TARGETING OF INFECTION</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/D014301/1</gtr:grantReference><gtr:abstractText>As a result of a BBSRC funded project we have generated a new 293T based cell line specifically for the production of metabolically biotin labelled lentiviral vectors. These bio-lentiviral vectors have been demonstrated to efficiently complex with streptavidin paramagnetic particles. This combination has resulted in the most efficient purification and concentration method yet described for lentiviral vectors. We wish to use the platform of these new biotin-lentiviral packaging cells to exemplify their value to the gene therapy community. By virtue of their biotinylated surface these viruses can be attached to specific cell binding proteins so that they can be targeted to specific sites of disease. Their unique properties also allow us to increase our knowledge of the cell derived accessory proteins that are also resident on the lentiviral surface. Information on the influence of these proteins on the process of lentiviral infection can then be applied to more efficient targeting of gene therapy vectors to specific sites of infection.</gtr:abstractText><gtr:technicalSummary>For lentiviral vectors we have succeeded in engineering an entirely new producer cell type in which the extracellular domain of LNGFR is fused to a biotin acceptor peptide (BAPref). Coordinate expression with the bacterial Bir A gene in human 293T cells results in metabolic biotinylation of a specific lysine residue in the BAP region. LNGFR-BAP-BIOTIN appears on the surface of lentiviral vector making them susceptible to Streptavidin capture. We now propose to use the platform bio-lentivector technology to increase the efficiency of targeting and to test the hypothesis that 'infection attenuated, and non-infectious lentiviral vectors can be manipulated to generate an exclusively ligand dependent, tissues specific infection of target cells'. To do this we will pursue two strategies: 1) Incorporation of cell/tissue specific ligands onto lentivirus particles, thus enabling them to regain infectivity only for the targeted cells. 2) Ligand dependent targeting of non-infectious vectors to specific cells, followed by a second stage targeting delivery of infection promoting factors, thus restricting infection to cells that have been successfully targeted by both components (the non-infectious virus, and the infection agent).</gtr:technicalSummary><gtr:fund><gtr:end>2010-07-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2006-07-31</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>197129</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cell Therapy Catapult</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Vector Industrialisation Project</gtr:description><gtr:id>9A230498-0F91-4115-BB67-492369BD5E01</gtr:id><gtr:impact>This project is contributing to the development of new therapies and therapeutic strategies, particularly with respect of the industrial scale manufacture of cell and gene therapy vectors, thus contributing both to better health care and to creation of wealth, including inward investment from outside the UK.</gtr:impact><gtr:partnerContribution>Funding of the initial studies, providing the vector manufacturing cell line and expertise in project management, accurate calculation of costs of goods. Cell and Gene Therapy Catapult is also providing expertise in the development of strategies aimed at reducing the cost of goods, risk-reduction for manufacturing campaigns and strategies for efficient large scale manufacture of clinical grade vectors. This project is underpinned by two previous BBSRC grants and directly affected by our current BBSRC supported project.</gtr:partnerContribution><gtr:piContribution>The aim of this recently initiated project is the development of GMP compatible procedures for the industrialisation of gene therapy products. The main focus of this specific project is the development of cell line/s with characteristics needed for large scale manufacture of a retrovirus vector encoding a specific T cell receptor (TCR).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>450000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR/BRC</gtr:department><gtr:description>Core Suppport for GMP facility</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research (NIHR)</gtr:fundingOrg><gtr:id>D72DCAE7-1DCB-4913-B65D-A12C33537890</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>275000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Efficacy/safety of CD80-IL-2 vs novel CD80-IL-15-IL-15R? vector for leukemia vaccine</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:fundingRef>NIH R21: AI099829-01A1</gtr:fundingRef><gtr:id>051ABADA-8F04-4C17-BE39-054B4666C199</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1200000</gtr:amountPounds><gtr:country>Singapore, Republic of</gtr:country><gtr:currCode>SGD</gtr:currCode><gtr:currCountryCode>Singapore</gtr:currCountryCode><gtr:currLang>en_SG</gtr:currLang><gtr:description>An immunisation strategy to prevent hepatocellular carcinoma</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>National Medical Research Council NMRC</gtr:fundingOrg><gtr:id>1191A765-285B-4CB8-8C26-EBD0D3826F4D</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>540000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Translational Research Program: Activation of multiple adjuvant pathways to improve AML vaccine efficacy</gtr:description><gtr:end>2016-06-02</gtr:end><gtr:fundingOrg>The Leukemia &amp; Lymphoma Society</gtr:fundingOrg><gtr:id>1974C633-0998-4D52-8330-0BB9D89DED77</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1093000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pre-emptive immune therapy to prevent relapse of myeloid malignancies</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:fundingRef>LLR 13007</gtr:fundingRef><gtr:id>335EF680-958B-4ADC-A8A9-1A8D8BC43C18</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Core Suppport for GMP facility</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Experimental Cancer Medicine Centre Network (ECMC)</gtr:fundingOrg><gtr:id>189605BC-B578-4FCB-BB7C-5096D7193801</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>This project has culminated in the development of novel manufacturing procedures for the generation of lentivirus and retrovirus based vectors for clinical use. This IP, and facilities generated has resulted in substantial collaborations with the biotech and pharmaceutical industries. Please see the Key Findings above for further details.</gtr:description><gtr:firstYearOfImpact>2012</gtr:firstYearOfImpact><gtr:id>FC550818-7DAB-4603-8830-CAA5C6345452</gtr:id><gtr:impactTypes/><gtr:sector>Education,Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>We have developed procedures for the fast manufacture of retrovirus and lentivirus vectors in compliance with the regulatory requirements for clinical use (GMP compliant procedures). These highly optimised procedures have enabled the production of high titre vectors (about 50,000 million infectious units of vector) from relatively small scale cultures (circa 10 litres), with greater than 50% recovery (frequently in excess of 70%) and minimal quantities of contaminating proteins and nucleic acids. This knowhow has recently been licensed on non-exclusive deals to the industry (Cellectis) in contracts producing in excess of &amp;pound;15 million pounds of income over the next 3 years.</gtr:description><gtr:id>7AAC1C5B-E9E5-4AC0-9D7D-0C4E7FC2701E</gtr:id><gtr:impact>We have produced, for regulatory approved clinical trials, the largest number of lenti- and retroviral vectors in Europe. Each of the 4 BBSRC supported projects have contributed to this outcome. We are now extending this expertise with a view to similarly innovative manufacture of Adeno Associated Virus (AAV) manufacture for clinical use.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>The processes developed in the course of this study have directly contributed to the success of subsequent contracts with the Industry, including Autolus and Cellectis (biotech and pharmaceutical companies.</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The production of viral vectors, in particular lentivirus and gamma-retrovirus in sufficient quantities and able to meet the regulatory standards of quality is particularly challenging. Using the technologies that were developed as part of our BBSRC supported projects, we have established a range of manufacturing, purification and concentration strategies that have enabled us to manufacture the largest number (academia or industry) of retroviral and lentivirus vectors for regulatory approved clinical trials in Europe. This extensive research and development programme has now culminated in over &amp;pound;15 million pound of income (2012 to 2019) for King's College London from overseas based companies.</gtr:description><gtr:id>0263EC21-EB20-43BE-A522-89CCF8931C44</gtr:id><gtr:impact>The background manufacturing IP and know-how is licensed (non-exclusive) to Cellectis and to Cell Therapy Catapult. Discussions are in progress with other organisations in taking similar non-exclusive licenses.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Development of GMP compliant manufacturing strategies for the production of clinical grade viral vectors</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>The main output of this project, in combination with BB/E005896/1 has been the development of novel procedures for biomarking of retrovirus and lentivirus based vectors. This technology, combined with the development of GMP facilities and development of GMP compliant procedures for the production of clinically suitable batches of these viral vectors have resulted in substantial further grant funding, two clinical trials for lentivirus based modification of autologous acute myeloid leukaemia (AML) cells to enable the expression of CD80 and IL-2, in order to generate an AML cell vaccine. These Phase-I clinical trials are currently in progress at King's College Hospital. In addition, the technologies developed and the facilities generated with the aid of these grants (BB/D014301/1 and BB/E005896/1) have enabled further collaborations with the pharmaceutical industry, including &amp;pound;2.4M worth projects with Roche Pharmaceuticals, &amp;pound;2.6M worth of contracts with Northwest Biotehrapeutics and &amp;pound;10.1M with Cellectis.</gtr:description><gtr:exploitationPathways>The viral vector manufacturing technologies and GMP facilities that are developed with the aid of these BBSRC supported project grants, in conjunction with further support from NIHR and Experimental Cancer Medicine initiative are now providing the basis for further collaborations with the pharmaceutical industry. We are in active discussions with Autolus, Pfizer and MedImmune. Autolus has already contracted projects worth over &amp;pound;500,000 for 2016/2017).</gtr:exploitationPathways><gtr:id>E784E581-3BEE-4E9D-A357-BCB7EA6A95F3</gtr:id><gtr:sectors><gtr:sector>Education,Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/29DBE936-BB24-46F0-A5EF-3BA66247BCDB"><gtr:id>29DBE936-BB24-46F0-A5EF-3BA66247BCDB</gtr:id><gtr:title>Metabolic biotinylation of lentiviral pseudotypes for scalable paramagnetic microparticle-dependent manipulation.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/148ff15d1264f46ff70d5454dc11a5b5"><gtr:id>148ff15d1264f46ff70d5454dc11a5b5</gtr:id><gtr:otherNames>Nesbeth D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F6D67C32-97B3-45D7-87C7-9C1322FE69A6"><gtr:id>F6D67C32-97B3-45D7-87C7-9C1322FE69A6</gtr:id><gtr:title>Lytic activity against primary AML cells is stimulated in vitro by an autologous whole cell vaccine expressing IL-2 and CD80.</gtr:title><gtr:parentPublicationTitle>Cancer immunology, immunotherapy : CII</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f26c68aa9ecea466134c7126ebe179aa"><gtr:id>f26c68aa9ecea466134c7126ebe179aa</gtr:id><gtr:otherNames>Hardwick N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0340-7004</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/839A251D-DF37-4824-BE17-F989DB0F8639"><gtr:id>839A251D-DF37-4824-BE17-F989DB0F8639</gtr:id><gtr:title>Immobilized metal affinity chromatography of histidine-tagged lentiviral vectors using monolithic adsorbents.</gtr:title><gtr:parentPublicationTitle>Journal of chromatography. A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/29091dfa0a7624fca6dba4fe584c0f22"><gtr:id>29091dfa0a7624fca6dba4fe584c0f22</gtr:id><gtr:otherNames>Cheeks MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9673</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1CDF11E2-4C65-474A-9FC2-9856BFCFD40D"><gtr:id>1CDF11E2-4C65-474A-9FC2-9856BFCFD40D</gtr:id><gtr:title>Active dendritic cell immunotherapy for glioblastoma: Current status and challenges.</gtr:title><gtr:parentPublicationTitle>British journal of neurosurgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d34d3ede29e8ba6b5936802fcccc0bfc"><gtr:id>d34d3ede29e8ba6b5936802fcccc0bfc</gtr:id><gtr:otherNames>Polyzoidis S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0268-8697</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1D6C7F50-9E54-4CAB-AD97-034BE8A3F435"><gtr:id>1D6C7F50-9E54-4CAB-AD97-034BE8A3F435</gtr:id><gtr:title>Identity, potency, in vivo viability, and scaling up production of lentiviral vector-induced dendritic cells for melanoma immunotherapy.</gtr:title><gtr:parentPublicationTitle>Human gene therapy methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e502bdff32788aaa0b74f26351d3421c"><gtr:id>e502bdff32788aaa0b74f26351d3421c</gtr:id><gtr:otherNames>Pincha M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1946-6536</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/D014301/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>